Abstract

Persistent pathogens have evolved to avoid elimination by the mammalian immune system including mechanisms to evade complement. Infections with African trypanosomes can persist for years and cause human and animal disease throughout sub-Saharan Africa. It is not known how trypanosomes limit the action of the alternative complement pathway. Here we identify an African trypanosome receptor for mammalian factor H, a negative regulator of the alternative pathway. Structural studies show how the receptor binds ligand, leaving inhibitory domains of factor H free to inactivate complement C3b deposited on the trypanosome surface. Receptor expression is highest in developmental stages transmitted to the tsetse fly vector and those exposed to blood meals in the tsetse gut. Receptor gene deletion reduced tsetse infection, identifying this receptor as a virulence factor for transmission. This demonstrates how a pathogen evolved a molecular mechanism to increase transmission to an insect vector by exploitation of a mammalian complement regulator.

African trypanosome infections can persist for years, but immune evasion mechanisms are not fully understood. Here, Macleod et al. identify a trypanosome receptor for mammalian factor H, a negative regulator of the alternative complement pathway, that increases parasite transmission to tsetse flies.

Details

Title
A receptor for the complement regulator factor H increases transmission of trypanosomes to tsetse flies
Author
Macleod, Olivia J, S 1   VIAFID ORCID Logo  ; Jean-Mathieu, Bart 2   VIAFID ORCID Logo  ; MacGregor, Paula 1   VIAFID ORCID Logo  ; Peacock, Lori 3 ; Savill, Nicholas J 4   VIAFID ORCID Logo  ; Hester Svenja 5 ; Ravel, Sophie 2 ; Sunter, Jack D 6   VIAFID ORCID Logo  ; Trevor Camilla 7 ; Rust, Steven 8 ; Vaughan, Tristan J 8 ; Minter, Ralph 8   VIAFID ORCID Logo  ; Shabaz, Mohammed 5   VIAFID ORCID Logo  ; Gibson, Wendy 3 ; Taylor, Martin C 9   VIAFID ORCID Logo  ; Higgins, Matthew K 5   VIAFID ORCID Logo  ; Carrington, Mark 1   VIAFID ORCID Logo 

 University of Cambridge, Department of Biochemistry, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934) 
 University of Montpellier, Intertryp, IRD, Cirad, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141) 
 University of Bristol, School of Biological Sciences, Bristol, UK (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603) 
 University of Edinburgh, Institute for Immunology and Infection Research, School of Biological Sciences, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
 University of Oxford, Department of Biochemistry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 Oxford Brookes University, Department of Biological and Medical Sciences, Oxford, UK (GRID:grid.7628.b) (ISNI:0000 0001 0726 8331) 
 University of Cambridge, Department of Biochemistry, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); AstraZeneca R&D, Department of Antibody Discovery and Protein Engineering, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 AstraZeneca R&D, Department of Antibody Discovery and Protein Engineering, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 London School of Hygiene and Tropical Medicine, Faculty of Infectious and Tropical diseases, London, UK (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2376714169
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.